Who Owns Skyrizi?
Skyrizi is owned by AbbVie Inc. (NYSE: ABBV), which developed the drug in collaboration with Boehringer Ingelheim and leads its global commercialization. The IL-23 inhibitor was first approved in 2019 and generated $17.56 billion in worldwide sales in FY2025, making it AbbVie's largest product and the successor to Humira as the company's flagship immunology franchise.
Skyrizi Timeline
GlobalOfficial Website
Who Owns Skyrizi?
- Parent Company: AbbVie Inc.
- Ownership Type: Product line
- Company Type: Publicly Traded
- Stock Ticker: NYSE: ABBV
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Skyrizi | AbbVie Inc. | Product line |
Where to Buy
Disclosure: We may earn commission from purchases
Skyrizi on AmazonHistory of Skyrizi
- Founded: 2019
- Founders: AbbVie and Boehringer Ingelheim (co-developed)
Risankizumab emerged from Boehringer Ingelheim's research on interleukin-23, a cytokine implicated in autoimmune inflammation. AbbVie partnered with Boehringer Ingelheim to develop it, selecting the p19 subunit approach that differentiated it from earlier IL-12/23 drugs such as Johnson & Johnson's Stelara.
The FDA first approved Skyrizi in April 2019 for moderate to severe plaque psoriasis, with European approval following. The launch arrived at a strategic moment: AbbVie knew Humira's U.S. exclusivity would end in 2023, and Skyrizi plus the JAK inhibitor Rinvoq, approved the same year, were positioned as the replacement franchise.
Label expansion drove the growth curve. Psoriatic arthritis approval followed the psoriasis launch, Crohn's disease was approved in 2022, and ulcerative colitis in 2024, turning Skyrizi from a dermatology drug into a full gastroenterology and rheumatology platform. An on-body injector presentation improved administration convenience.
Sales climbed steeply: from under $2 billion in early years to $17.56 billion worldwide in FY2025, a Q4 growth rate above 30 percent. The trajectory made Skyrizi the fastest-scaling immunology product in AbbVie's history and, by 2025, one of the top-selling drugs globally.
The brand's next phase extends into new indications including giant cell arteritis studies and lifecycle presentations, with AbbVie managing it as the centerpiece of its post-Humira growth story through at least the early 2030s under current patent protection.
About AbbVie Inc.
What does AbbVie own?
AbbVie owns a portfolio of prescription drug brands including Skyrizi, Rinvoq, Humira, Imbruvica, Venclexta, Vraylar, Ubrelvy, Qulipta, and Elahere, plus the aesthetics products Botox Cosmetic and Juvederm acquired through the 2020 Allergan deal. All are internally held product brands rather than separate subsidiaries.
Is AbbVie publicly traded?
Yes. AbbVie trades on the New York Stock Exchange under ticker ABBV and is a component of the S&P 500. It has traded publicly since its January 2013 spin-off from Abbott Laboratories, and Abbott retains no ownership stake.
Who founded AbbVie?
AbbVie was not founded by individuals but created as a corporate spin-off from Abbott Laboratories in 2013, led at launch by CEO Richard A. Gonzalez. Its operating heritage traces to Dr. Wallace C. Abbott, who founded Abbott's predecessor drug company in Chicago in 1888.
Where is AbbVie headquartered?
AbbVie is headquartered in North Chicago, Illinois, in the same suburban Chicago corridor where Abbott has long been based. Its principal offices sit at 1 North Waukegan Road.
How many brands does AbbVie own?
AbbVie markets roughly a dozen major product brands, led by Skyrizi, Rinvoq, Humira, Botox, Juvederm, Imbruvica, and Venclexta, plus smaller products across eye care and neuroscience. Unlike consumer conglomerates, its brands are individual prescription medicines rather than retail labels.
Who owns AbbVie?
AbbVie is owned by public shareholders, with Vanguard, BlackRock, and State Street as the largest institutional holders. Robert A. Michael serves as chairman and chief executive officer. No founding family or single shareholder controls the company.
What happened to Humira?
U.S. biosimilar competitors launched in January 2023 after AbbVie's patent settlements allowed entry. Humira worldwide revenue fell from a $21.2 billion peak in 2022 to $4.54 billion in 2025, while Skyrizi and Rinvoq grew to replace it, pushing total company revenue to a record $61.16 billion.
- Founded: 2013
- Headquarters: North Chicago, Illinois, USA
- Company Type: Publicly Traded
- Stock: NYSE: ABBV
- Revenue: $61.16 billion (FY2025)
- Employees: Approximately 55,000
Where Is Skyrizi Made / Based?
- Headquarters: North Chicago, Illinois, USA
- Manufacturing / Operations: United States, Germany, Ireland
Skyrizi Categories & Tags
Skyrizi Recalls & Controversies
Skyrizi has not been subject to major safety recalls since its 2019 approval. Like all immunosuppressive biologics it carries labeled warnings for infections and, in its class, considerations around hypersensitivity and liver enzyme monitoring in Crohn's patients.
The brand inherits the broader scrutiny applied to AbbVie's pricing practices. Skyrizi's launch and growth occurred amid congressional and public criticism of specialty drug pricing, and as a top-selling drug it is a plausible candidate for future Medicare price negotiation as the IRA program expands to later drug cohorts. No Medicare negotiation has applied to Skyrizi through September 2026.
Skyrizi Ownership: Pros & Cons
Advantages
- +Backed by AbbVie's $13.8 billion annual adjusted R&D budget
- +Four approved indications create multiple revenue engines
- +Top-selling immunology drug globally with 30 percent-plus growth
- +Patent protection extends into the early 2030s
- +Part of a proven post-patent-cliff transition strategy
Considerations
- -Single-product concentration risk for both brand and parent
- -Medicare price negotiation exposure in future rounds
- -Immunology class competition from Tremfya, Entyvio, and others
- -Long-term safety profile still accumulating real-world data
- -Specialty pricing faces persistent policy pressure
Frequently Asked Questions About Skyrizi
Sources & Further Reading
Competitors to Skyrizi
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Novartis | Switzerland | 2015 | Premium | United states | All Genders | |
| Sanofi | USA (Regeneron) | 2017 | Specialty | Global | All-ages | |
| Takeda | Japan | 2014 | Mass market | Global | All Genders | |
| Bristol Myers Squibb | USA | 2014 | Mass market | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsCosentyx
Owned by Novartis
Prescription biologic medication treating psoriasis, psoriatic arthritis, and other autoimmune conditions.
biologicautoimmunepsoriasis
Healthcare PharmaceuticalsDupixent
Owned by Sanofi
Blockbuster biologic medication (dupilumab) co-developed by Sanofi and Regeneron Pharmaceuticals. FDA approved in 2017. Over 1.4 million active patients worldwide. Global net sales of $17.8 billion in 2025.
immunologyatopic-dermatitisdupilumab
Healthcare PharmaceuticalsEntyvio
Owned by Takeda Pharmaceutical Company
Prescription biologic medication for treating inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Takeda's top-selling product, generating over $5 billion annually.
gastroenterologyinflammatory-bowel-diseasecrohns-disease
Healthcare PharmaceuticalsOpdivo
Owned by Bristol Myers Squibb Company
Opdivo (nivolumab) is Bristol Myers Squibb's flagship cancer immunotherapy, an anti-PD-1 antibody approved across more than a dozen tumor types.
prescription-drugoncologyimmunotherapy
Competitive Analysis
Market Positioning: Skyrizi competes with 4 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Skyrizi
Looking for brands with different ownership structures? These similar brands are not owned by AbbVie Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsBoots
Owned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
pharmacyhealth-beautyuk-retail
Privately Owned
Boots is privately owned, unlike Skyrizi which is under a publicly traded parent company.
Healthcare PharmaceuticalsDuane Reade
Owned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
pharmacydrugstorenew-york
Privately Owned
Duane Reade is privately owned, unlike Skyrizi which is under a publicly traded parent company.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Skyrizi which is under a publicly traded parent company.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike Skyrizi which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Skyrizi which is under a publicly traded parent company.
Healthcare PharmaceuticalsWalgreens
Owned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
pharmacydrugstoreretail-pharmacy
Privately Owned
Walgreens is privately owned, unlike Skyrizi which is under a publicly traded parent company.
AbbVie Inc. Stock Information
Jobs at AbbVie Inc.
Latest News About Skyrizi
Related Articles About Skyrizi
View more articles
Global
Regional Brands That Got Swallowed by Multinationals
La Serenissima is now Arcor/Danone. Innovist is now L'Oreal. Zabka is being bought by Couche-Tard for $8.6B. S Brands is now Wipro. Discover regional brands swallowed by multinationals. Explore our database.
Who Brands StaffSep 26, 2026
GlobalAcquisitionsBrand Ownership
Global
Why Some Global Brands Have Different Names Abroad
Lay's is Walkers in the UK. Burger King is Hungry Jack's in Australia. KFC is PFK in Quebec. Mr. Clean is Don Limpio in Spain. Discover why global brands have different names abroad. Explore our database.
Who Brands StaffSep 24, 2026
GlobalInternationalBrand Ownership
Global
Brands That Mean Different Things in Different Countries
Fila is premium in Taipei but budget in Europe. Muller yogurt means indulgence in Italy but health in Germany. Starbucks' Tank Day caused boycotts in Korea. Discover brands that mean different things in different countries. Explore our database.
Who Brands StaffSep 23, 2026
GlobalInternationalBrand Ownership
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription